Evidence map›Paper›PMID 35214781›Full record

ArticleVaccines2022

Demographic Characteristics and Status of Vaccinated Individuals with a History of COVID-19 Infection Pre- or Post-Vaccination: A Descriptive Study of a Nationally Representative Sample in Saudi Arabia.

Yazed AlRuthia, Haya F Al-Salloum, Omar A Almohammed, Amani S Alqahtani, Hana A Al-Abdulkarim, Yousef M Alsofayan, Sami S Almudarra, Sara H AlQahtani, Abdullah Almutlaq, Khaled Alabdulkareem and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yazed AlRuthiaDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.ORCID 0000-0002-0029-5924
Haya F Al-SalloumDepartment of Pharmacy, King Khalid University Hospital, King Saud University Medical City, Riyadh 12372, Saudi Arabia.ORCID 0000-0001-7433-9523
Omar A AlmohammedDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.ORCID 0000-0002-3792-4106
Amani S AlqahtaniSaudi Food and Drug Authority, Riyadh 13513, Saudi Arabia.ORCID 0000-0002-6320-118X
Hana A Al-AbdulkarimDrug Policy and Economic Center, National Guard Health Affairs, Riyadh 14812, Saudi Arabia.
Yousef M AlsofayanExecutive Directorate of Medical Affairs, Saudi Red Crescent Authority, Riyadh 11129, Saudi Arabia.
Sami S AlmudarraGulf Center for Disease Prevention and Control, Gulf Health Council, Riyadh 12511, Saudi Arabia.ORCID 0000-0001-6653-9592
Sara H AlQahtaniDepartment of Public Health, Ministry of Health, Riyadh 11176, Saudi Arabia.
Abdullah AlmutlaqRheumatology Division, Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh 11564, Saudi Arabia.
Khaled AlabdulkareemAssisting Deputyship for Primary Health Care, Ministry of Health, Riyadh 11176, Saudi Arabia.
Bander BalkhiDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.ORCID 0000-0003-3801-5497
Hamoud T AlmutairiDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Abdullah S AlanaziDepartment of Clinical Pharmacy, College of Pharmacy, Jouf University, Skaka 42421, Saudi Arabia.ORCID 0000-0002-8120-4018
Yousif A AsiriDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.

Funding

Researchers Supporting Project, King Saud University, Riyadh, Saudi Arabia (RSP-2021/16)
6 · The paper itself

Abstract

backgroundSaudi Arabia expedited the approval of some COVID-19 vaccines and launched mass vaccination campaigns. The aim of this study was to describe the demographics of vaccinated COVID-19 cases and compare the mortality rates of COVID-19 cases who were infected post-vaccination in Saudi Arabia.

methodsThis was a retrospective cohort study. We retrieved data for COVID-19 cases who were infected pre- or post-vaccination and had received at least one injection of the Oxford-AstraZeneca or Pfizer-BioNTech vaccine from 4 December 2020 to 15 October 2021.

resultsThe number of patients who were infected and had received at least one dose of a COVID-19 vaccine was 281,744. Approximately 45% of subjects were infected post-vaccination, and 75% of subjects had received the Pfizer-BioNTech vaccine. Only 0.342% of the patients who were infected post-vaccination died, and 447 patients were admitted to ICUs. Most of the patients who were infected with COVID-19 post-vaccination and were admitted to ICUs (69.84%) had received only one dose of the vaccine (

conclusionsVaccines are vital in combating the COVID-19 pandemic. The results of this study show no difference between the Pfizer-BioNTech and Oxford-AstraZeneca vaccines in the rate of mortality. However, the number of vaccine doses was significantly associated with a lower risk of mortality. Future studies should examine the effectiveness of different COVID-19 vaccines using real-world data and more robust designs.

Indexed as

COVID-19demographicsOxford–AstraZeneca COVID-19 vaccinePfizer COVID-19 vaccineSaudi Arabia

Identifiers

PMID35214781
PMCPMC8875240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.